WO2012077968A3 - Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof - Google Patents

Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof Download PDF

Info

Publication number
WO2012077968A3
WO2012077968A3 PCT/KR2011/009413 KR2011009413W WO2012077968A3 WO 2012077968 A3 WO2012077968 A3 WO 2012077968A3 KR 2011009413 W KR2011009413 W KR 2011009413W WO 2012077968 A3 WO2012077968 A3 WO 2012077968A3
Authority
WO
WIPO (PCT)
Prior art keywords
valsartan
lercanidipine hydrochloride
preparation
present
complex formulation
Prior art date
Application number
PCT/KR2011/009413
Other languages
French (fr)
Other versions
WO2012077968A2 (en
Inventor
Young Sik Chung
Soo Ah Park
Ree Sun Kim
Sung Il Kim
Jae Hyeon Juhn
Dong Kyu Kim
Yoo Rin Kim
Hee Dong Park
Seong Jae Park
Sung Hack Lee
Ju Hyun Kim
Min Young Jung
Original Assignee
Lg Life Sciences Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46207595&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2012077968(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SG2013038211A priority Critical patent/SG190326A1/en
Priority to BR112013013415A priority patent/BR112013013415A2/en
Priority to UAA201307936A priority patent/UA108277C2/en
Priority to AU2011339150A priority patent/AU2011339150B2/en
Priority to MX2013005716A priority patent/MX2013005716A/en
Application filed by Lg Life Sciences Ltd. filed Critical Lg Life Sciences Ltd.
Priority to EA201390844A priority patent/EA201390844A1/en
Priority to CN201180058951.9A priority patent/CN103249415B/en
Priority to EP11847739.7A priority patent/EP2648730A4/en
Publication of WO2012077968A2 publication Critical patent/WO2012077968A2/en
Publication of WO2012077968A3 publication Critical patent/WO2012077968A3/en
Priority to TNP2013000212A priority patent/TN2013000212A1/en
Priority to IL226449A priority patent/IL226449A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising lercanidipine hydrochloride and valsartan as active components and a method for the preparation thereof. The pharmaceutical composition comprising lercanidipine hydrochloride and valsartan according to the present invention has a superior effect on the prevention and treatment of cardiovascular diseases and their complex diseases, and reduces the adverse effects of each component. In addition, the present composition comprises lercanidipine hydrochloride and valsartan in a separated form so as to increase the dissolution rates of both components and reduce the adverse effects.
PCT/KR2011/009413 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof WO2012077968A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP11847739.7A EP2648730A4 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
BR112013013415A BR112013013415A2 (en) 2010-12-09 2011-12-07 pharmaceutical composition, and method for preparing a pharmaceutical composition
UAA201307936A UA108277C2 (en) 2010-12-09 2011-12-07 Complex preparation containing lercanidipine hydrochloride and valsartan, and method for production
AU2011339150A AU2011339150B2 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
MX2013005716A MX2013005716A (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof.
SG2013038211A SG190326A1 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
EA201390844A EA201390844A1 (en) 2010-12-09 2011-12-07 COMPLEX COMPOSITION CONTAINING LERCANIDIPINE HYDROCHLORIDE AND VALSARTAN AND METHOD FOR ITS PREPARATION
CN201180058951.9A CN103249415B (en) 2010-12-09 2011-12-07 Compound formulation comprising Lercanidipine hydrochloride and Valsartan and preparation method thereof
TNP2013000212A TN2013000212A1 (en) 2011-12-07 2013-05-15 Complex formulation comprising lercanidipine hydrochloride and valsartan and mathod for the preparation therof
IL226449A IL226449A0 (en) 2010-12-09 2013-05-20 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100125804 2010-12-09
KR10-2010-0125804 2010-12-09

Publications (2)

Publication Number Publication Date
WO2012077968A2 WO2012077968A2 (en) 2012-06-14
WO2012077968A3 true WO2012077968A3 (en) 2012-07-26

Family

ID=46207595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/009413 WO2012077968A2 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof

Country Status (17)

Country Link
EP (1) EP2648730A4 (en)
KR (1) KR101414814B1 (en)
CN (1) CN103249415B (en)
AR (1) AR084195A1 (en)
AU (1) AU2011339150B2 (en)
BR (1) BR112013013415A2 (en)
CL (1) CL2013001626A1 (en)
CO (1) CO6721030A2 (en)
DO (1) DOP2013000115A (en)
EA (1) EA201390844A1 (en)
IL (1) IL226449A0 (en)
MX (1) MX2013005716A (en)
PE (1) PE20140699A1 (en)
SG (1) SG190326A1 (en)
UA (1) UA108277C2 (en)
UY (1) UY33772A (en)
WO (1) WO2012077968A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102755322B (en) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 Compound preparation of lercanidipine and atorvastatin
CA2903961A1 (en) * 2013-03-12 2014-09-18 Lg Life Sciences Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
US11382866B2 (en) * 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
KR102233986B1 (en) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 Solid pharmaceutical composition comprising lafutidine and irsogladin and process for producing thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
US20070105912A1 (en) * 2003-12-01 2007-05-10 Per Holm Pharmaceutical compositions comprising lercanidipine
US20100047341A1 (en) * 2006-10-10 2010-02-25 Hanall Pharmaceutical Co., Ltd. Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theory

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5110697B2 (en) * 2005-06-27 2012-12-26 第一三共株式会社 Solid preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
US20070105912A1 (en) * 2003-12-01 2007-05-10 Per Holm Pharmaceutical compositions comprising lercanidipine
US20100047341A1 (en) * 2006-10-10 2010-02-25 Hanall Pharmaceutical Co., Ltd. Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theory

Also Published As

Publication number Publication date
UY33772A (en) 2012-07-31
EP2648730A4 (en) 2014-08-06
SG190326A1 (en) 2013-06-28
EA201390844A1 (en) 2013-11-29
MX2013005716A (en) 2013-06-12
WO2012077968A2 (en) 2012-06-14
DOP2013000115A (en) 2014-07-31
BR112013013415A2 (en) 2019-09-24
PE20140699A1 (en) 2014-06-13
KR20120089787A (en) 2012-08-13
KR101414814B1 (en) 2014-07-21
EP2648730A2 (en) 2013-10-16
CL2013001626A1 (en) 2013-10-04
AU2011339150B2 (en) 2015-09-10
AR084195A1 (en) 2013-04-24
IL226449A0 (en) 2013-07-31
CN103249415A (en) 2013-08-14
AU2011339150A1 (en) 2013-06-06
CN103249415B (en) 2017-12-12
UA108277C2 (en) 2015-04-10
CO6721030A2 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
EP2522653A4 (en) Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient
WO2012042224A8 (en) Pharmaceutical composition comprising deferasirox
WO2010092090A3 (en) Novel salts of sitagliptin
WO2012021715A3 (en) Stable formulations of linaclotide
WO2010111640A3 (en) Anti-influenza formulations and methods
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
PH12015500653A1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
WO2012053009A3 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
WO2010090494A3 (en) Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2012077968A3 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
WO2012024583A3 (en) Oxysterol compounds
WO2014064652A3 (en) Stable pharmaceutical composition of peginterferon alpha-2b
WO2013100718A3 (en) Pharmaceutical composition for preventing or treating inflammatory diseases or asthma, containing lagerstroemia ovalifolia extract or fraction thereof as active ingredient
WO2012155226A8 (en) Method for producing pyrostegia venusta derivatives, pyrostegia venusta derivatives, pharmaceutical compositions and uses thereof
WO2014001267A3 (en) Medicament form for release of active ingredients
WO2011093831A3 (en) Effervescent formulations comprising cefprozil as active agent
WO2012007758A3 (en) Pharmaceutical formulations
WO2009108017A3 (en) New pyruvate derivatives with neuroprotective effect, process for preparing the same and pharmaceutical composition comprising the same
TN2013000212A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and mathod for the preparation therof
WO2011139255A3 (en) Pharmaceutical compositions comprising cefetamet

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11847739

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12013500980

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 226449

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/005716

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 001346-2013

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 2011339150

Country of ref document: AU

Date of ref document: 20111207

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013001626

Country of ref document: CL

WWE Wipo information: entry into national phase

Ref document number: 2013/06919

Country of ref document: TR

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011847739

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13130

Country of ref document: GE

Ref document number: 13147794

Country of ref document: CO

Ref document number: 2011847739

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201390844

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: A201307936

Country of ref document: UA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013013415

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013013415

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130529